• Markets
• News

• Sangamo Therapeutics Inc SGMO.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -66 cents. The mean expectation of seven analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -20 cents to -8 cents per share.

• Revenue fell 94.8% to $356.00 thousand from a year ago; analysts expected $8.26 million.

• Sangamo Therapeutics Inc's reported EPS for the quarter was a loss of 18 cents​.

• The company reported a quarterly loss of $36.13 million.

• Sangamo Therapeutics Inc shares had risen by 114.3% this quarter and gained 41.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.9% in the last three months.​

• In the last 30 days, there have been earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $3.00

This summary was machine generated from LSEG data August 6 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)